retatrutide phase 2 results RETATRUTIDE: The “Next Big Fat Loss Peptide” — But Here's What You NEED To Know 👀💉 is one of the newest peptides being talked about in the fitness and weight loss ESC 2024: Retatrutide improves lipid

The Phase 2 dose-finding trial (N=338), published in the New England Journal of Medicine in 2023 (DOI: 10.1056/NEJMoa2301972), randomized participants with obesity (BMI 30-50) to retatrutide at doses ranging from 0.5mg to 12mg weekly or placebo over 48 weeks

For people who already qualify for GLP-1 therapy because of diabetes or obesity especially cancer survivors the potential cancer benefits may become an additional factor in shared decision-making with their healthcare team

The injectable version aligns exactly with most clinical studies and the regimen employed by Ozempic and Wegovy

No matter what the individual is able to do behaviorally or psychologically, they couldn't fight that

During Your IV Sit back, relax, and let your body soak up the good stuff